Last reviewed · How we verify
NCT05745077
Using Data to Achieve Surgical Health Equity in the Community
NA trial testing Telemedicine Consultation in Gallbladder Disease in 60 participants. Completed in 21 May 2024.
4 March 2024
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 16 February 2023 |
| Primary completion | 4 March 2024 |
| Estimated completion | 21 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Telemedicine Consultation
- Traditional Care
Conditions studied
- Gallbladder Disease — all drugs for Gallbladder Disease →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with Gallbladder Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this retrospective cohort and pragmatic pilot trial is to examine the social determinants of health in racial and ethnic minority patients from socially vulnerable backgrounds who have Gallbladder Disease (GBD). The main questions it aims to answer are: 1. What racial barriers in outcome exist for socially vulnerable patients with gallbladder disease? 2. How effective is telemedicine consultation in improving surgical outcomes for socially vulnerable patients with gallbladder disease? Study participants will be asked to undergo telemedicine consultation in place of regular consultation with their doctor before undergoing treatment. Researchers will compare the telemedicine consultation groups with traditional care patients to see if telemedicine consultation is effective at reducing surgical disparity outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Telemedicine and Access to Elective Cholecystectomy for Socially Vulnerable Adults: A Pilot Randomized Clinical Trial.
Bakillah E, Harbison S, Rosato FE, Altieri MS, et al · · 2024 · PMID 39382898 · DOI 10.1001/jamanetworkopen.2024.38137
Verify or expand the search:
- PubMed search for NCT05745077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Telemedicine Consultation
Trials testing the same drug.
- NCT04806477 — Diagnostic Accuracy Comparison Between Telemedicine and Face-to-face Consultations in Respiratory Infection Patients. · NA · completed
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05745077 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 6 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05745077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing